BMP-2 signaling in ovarian cancer and its association with poor prognosis

Journal of Ovarian Research

Volumn 2, Issue 1, 2009, Pages

  Le Page, Cécile ^a   Puiffe, Marie Line ^a   Meunier, Liliane ^a   Zietarska, Magdalena ^a   De Ladurantaye, Manon ^a   Tonin, Patricia N ^b,c   Provencher, Diane ^a,d   Mes Masson, Anne Marie ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; INHIBITOR OF DIFFERENTIATION 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; RECOMBINANT PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR SNAIL;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; ASSAY; CANCER CELL CULTURE; CANCER PATIENT; CARCINOGENESIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPHEROID CELL; SURVIVAL; TISSUE SECTION; WESTERN BLOTTING;

EID: 70349913078     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-2-4     Document Type: Article

References (41)

1. Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer. C Le Page V Ouellet J Madore F Ren TJ Hudson PN Tonin DM Provencher AM Mes-Masson, Br J Cancer 2006 94 3 436 445 10.1038/sj.bjc.6602933 16421595
2. Predicting biomarkers for ovarian cancer using gene-expression microarrays. TR Adib S Henderson C Perrett D Hewitt D Bourmpoulia J Ledermann C Boshoff, Br J Cancer 2004 90 3 686 692 10.1038/sj.bjc.6601603 14760385
3. Microarray analysis of differentially expressed genes associated with human ovarian cancer. BC Lee K Cha S Avraham HK Avraham, Int J Oncol 2004 24 4 847 851 15010821
4. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. KH Lu AP Patterson L Wang RT Marquez EN Atkinson KA Baggerly LR Ramoth DG Rosen J Liu I Hellstrom D Smith L Hartmann D Fishman A Berchuck R Schmandt R Whitaker DM Gershenson GB Mills RC Bast Jr, Clin Cancer Res 2004 10 10 3291 3300 10.1158/1078-0432.CCR-03- 0409 15161682
5. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. K Hibbs KM Skubitz SE Pambuccian RC Casey KM Burleson TR Oegema Jr JJ Thiele SM Grindle RL Bliss AP Skubitz, Am J Pathol 2004 165 2 397 414 15277215
6. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential. S Warrenfeltz S Pavlik S Datta ET Kraemer B Benigno JF McDonald, Mol Cancer 2004 3 27 15471544 10.1186/1476-4598-3-27 (Pubitemid 40230545)
7. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. AD Santin F Zhan S Bellone M Palmieri S Cane E Bignotti S Anfossi M Gokden D Dunn JJ Roman TJ O'Brien E Tian MJ Cannon J Shaughnessy Jr S Pecorelli, Int J Cancer 2004 112 1 14 25 10.1002/ijc.20408 15305371
8. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. H Donninger T Bonome M Radonovich CA Pise-Masison J Brady JH Shih JC Barrett MJ Birrer, Oncogene 2004 23 49 8065 8077 10.1038/sj.onc.1207959 15361855
9. Gene expression patterns that characterize advanced stage serous ovarian cancers. JM Lancaster HK Dressman RS Whitaker L Havrilesky J Gray JR Marks JR Nevins A Berchuck, J Soc Gynecol Investig 2004 11 1 51 59 10.1016/j.jsgi.2003. 07.004 14706684
10. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. C Le Page V Ouellet J Madore TJ Hudson PN Tonin DM Provencher AM Mes-Masson, Int J Cancer 2006 118 7 1750 1758 10.1002/ijc.21521 16217764
11. Signature of a silent killer: expression profiling in epithelial ovarian cancer. C Le Page D Provencher CM Maugard V Ouellet AM Mes-Masson, Expert Rev Mol Diagn 2004 4 2 157 167 10.1586/14737159.4.2.157 14995903
12. Smads and early developmental signaling by the TGFbeta superfamily. M Whitman, Genes Dev 1998 12 16 2445 2462 10.1101/gad.12.16.2445 9716398
13. Modulation of BMP signaling by noggin is required for induction of the secondary (nontylotrich) hair follicles. VA Botchkarev NV Botchkareva AA Sharov K Funa O Huber BA Gilchrest, J Invest Dermatol 2002 118 1 3 10 10.1046/j.1523-1747.2002.01645.x 11851869
14. Bone morphogenetic proteins in melanoma: angel or devil? MY Hsu S Rovinsky S Penmatcha M Herlyn D Muirhead, Cancer Metastasis Rev 2005 24 2 251 263 10.1007/s10555-005-1575-y 15986135
15. Bone morphogenetic proteins and their receptor signaling in prostate cancer. L Ye JM Lewis-Russell HG Kyanaston WG Jiang, Histol Histopathol 2007 22 10 1129 1147 17616940
16. Bone morphogenetic proteins. D Chen M Zhao GR Mundy, Growth Factors 2004 22 4 233 241 10.1080/08977190412331279890 15621726
17. Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. M Suzawa Y Takeuchi S Fukumoto S Kato N Ueno K Miyazono T Matsumoto T Fujita, Endocrinology 1999 140 5 2125 2133 10.1210/en.140.5.2125 10218963
18. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. J Kleeff H Maruyama T Ishiwata H Sawhney H Friess MW Buchler M Korc, Gastroenterology 1999 116 5 1202 1216 10.1016/S0016-5085(99)70024-7 10220513
19. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. H Ide T Yoshida N Matsumoto K Aoki Y Osada T Sugimura M Terada, Cancer Res 1997 57 22 5022 5027 9371496
20. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). A Franzen NE Heldin, Biochem Biophys Res Commun 2001 285 3 773 781 10.1006/bbrc.2001.5212 11453659
21. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells. JH Clement M Raida J Sanger R Bicknell J Liu A Naumann A Geyer A Waldau P Hortschansky A Schmidt K Höffken S Wölft AL Harris, Int J Oncol 2005 27 2 401 407 16010421
22. BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. XZ Wen S Miyake Y Akiyama Y Yuasa, Biochem Biophys Res Commun 2004 316 1 100 106 10.1016/j.bbrc.2004.02.016 15003517
23. Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. M Raida JH Clement K Ameri C Han RD Leek AL Harris, Int J Oncol 2005 26 6 1465 1470 15870857
24. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. TB Ro RU Holt AT Brenne H Hjorth-Hansen A Waage O Hjertner A Sundan M Borset, Oncogene 2004 23 17 3024 3032 10.1038/sj.onc.1207386 14691444
25. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. S Chen DC Guttridge E Tang S Shi K Guan CY Wang, J Biol Chem 2001 276 42 39259 39263 10.1074/jbc.M105335200 11500509
26. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. BL Theriault TG Shepherd ML Mujoomdar MW Nachtigal, Carcinogenesis 2007 28 6 1153 1162 10.1093/carcin/bgm015 17272306
27. Signal transduction of bone morphogenetic protein receptors. A Nohe E Keating P Knaus NO Petersen, Cell Signal 2004 16 3 291 299 10.1016/j.cellsig. 2003.08.011 14687659
28. Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer. MC Quinn DM Provencher A-M Mes-Masson PN Tonin, Mol Carcinog 2008 19123201
29. BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-kappaB activation. K Sugimori K Matsui H Motomura T Tokoro J Wang S Higa T Kimura I Kitajima, J Bone Miner Metab 2005 23 6 411 419 10.1007/s00774-005-0622-7 16261446
30. TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB. SW Lee SI Han HH Kim ZH Lee, J Biochem Mol Biol 2002 35 4 371 376 12296995
31. Chordin is underexpressed in ovarian tumors and reduces tumor cell motility. F Moll C Millet D Noel B Orsetti A Bardin D Katsaros C Jorgensen M Garcia C Theillet P Pujol V François, FASEB J 2006 20 2 240 250 10.1096/fj.05-4126com 16449796
32. Characterization of four novel epithelial ovarian cancer cell lines. DM Provencher H Lounis L Champoux M Tetrault EN Manderson JC Wang P Eydoux R Savoie PN Tonin AM Mes-Masson, In Vitro Cell Dev Biol Anim 2000 36 6 357 361 10.1290/1071-2690(2000)036<0357:COFNEO2.0.CO;2 10949993
33. Characterization of three new serous epithelial ovarian cancer cell lines. V Ouellet M Zietarska L Portelance J Lafontaine J Madore ML Puiffe SL Arcand Z Shen J Hebert PN Tonin DM Provencher AM Mes-Masson, BMC Cancer 2008 8 1 152 18507860 10.1186/1471-2407-8-152
34. A simplified method to culture human ovarian surface epithelium. PA Kruk SL Maines-Bandiera N Auersperg, Lab Invest 1990 63 1 132 136 2374399
35. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. H Lounis D Provencher C Godbout D Fink MJ Milot AM Mes-Masson, Exp Cell Res 1994 215 2 303 309 10.1006/excr.1994.1346 7526992
36. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. C Le Page J Sanceau JC Drapier J Wietzerbin, Biochem Biophys Res Commun 1998 243 2 451 457 10.1006/bbrc.1998.8113 9480829
37. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). M Zietarska CM Maugard A Filali-Mouhim M Alam-Fahmy PN Tonin DM Provencher AM Mes-Masson, Mol Carcinog 2007 46 10 872 885 10.1002/mc.20315 17455221
38. Involvement of ERK in BMP-2 induced osteoblastic differentiation of mesenchymal progenitor cell line C3H10T1/2. J Lou Y Tu S Li PR Manske, Biochem Biophys Res Commun 2000 268 3 757 762 10.1006/bbrc.2000.2210 10679278
39. Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells. TG Shepherd MW Nachtigal, Endocrinology 2003 144 8 3306 3314 10.1210/en.2003-0185 12865307
40. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. EM Langenfeld SE Calvano F Abou-Nukta SF Lowry P Amenta J Langenfeld, Carcinogenesis 2003 24 9 1445 1454 10.1093/carcin/bgg100 12819188
41. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. BT Feeley SC Gamradt WK Hsu N Liu L Krenek P Robbins J Huard JR Lieberman, J Bone Miner Res 2005 20 12 2189 2199 10.1359/JBMR.050802 16294272